Evidence map›Paper›PMID 41444724›Full record

ArticleScientific reports2025

Development of a 3D-printable bioactive polycaprolactone-collagen peptides filament for biomedical applications.

Stefano Cantella, Silvia Badini, Carlotta Bollati, Mushtaq Alam Madar Saheb, Roberto Viganò, Carmen Lammi, Raffaele Pugliese, Serena Graziosi

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Stefano CantellaSchool of Industrial and Information Engineering, Politecnico di Milano, 20133, Milan, Italy.ORCID 0009-0000-9552-9326
Silvia BadiniNeMO Lab Research Center, ASST GOM Niguarda Cà Granda Hospital, 20152, Milan, Italy.ORCID 0009-0005-0770-6254
Carlotta BollatiDepartment of Pharmaceutical Sciences, University of Milan, 20133, Milan, Italy.ORCID 0000-0002-5698-1325
Mushtaq Alam Madar SahebDepartment of Mechanical Engineering, Politecnico di Milano, 20156, Milan, Italy.ORCID 0000-0002-7789-0019
Roberto ViganòDepartment of Mechanical Engineering, Politecnico di Milano, 20156, Milan, Italy.ORCID 0000-0003-2717-533X
Carmen LammiDepartment of Pharmaceutical Sciences, University of Milan, 20133, Milan, Italy.ORCID 0000-0002-7428-4486
Raffaele PuglieseNeMO Lab Research Center, ASST GOM Niguarda Cà Granda Hospital, 20152, Milan, Italy. raffaele.pugliese@nemolab.it.ORCID 0000-0001-7669-4457
Serena GraziosiDepartment of Mechanical Engineering, Politecnico di Milano, 20156, Milan, Italy. serena.graziosi@polimi.it.ORCID 0000-0002-6103-9107

Funding

European Union - NextGenerationEU CUP D53D23003740006
6 · The paper itself

Abstract

This study presents a scalable, nontoxic method for fabricating a 3D printable polycaprolactone (PCL)-collagen peptides composite filament via solvent-assisted blending and a customized desktop filament extrusion system. Virgin and recycled PCL feedstocks were used to study the matrix characteristics. Scanning electron microscopy, X-ray diffraction, differential scanning calorimetry, thermogravimetric analysis, and intrinsic fluorescence spectroscopy confirmed that the composite maintains PCL's inherent crystalline and thermal properties. It also exhibits intrinsic bioactive capabilities provided by the collagen peptides. Filaments with diameters suitable for the Fused Filament Fabrication 3D printing were obtained. Tests demonstrated that the recycled matrix and the lab-scale process reduce the tensile modulus of the material. At the same time, collagen peptides enhanced tensile stiffness by creating intermolecular hydrogen bonding with the PCL. The biocompatibility of the composite has also been confirmed, while degradability studies have shown the tunability of the PCL degradation rate. Additionally, examples of 3D-printed scaffolds based on Triply Periodic Minimal Surfaces have been successfully fabricated using the PCL-collagen peptide filament. Therefore, this study demonstrates that integrating collagen peptides into a PCL matrix represents a viable, nontoxic, affordable, and promising approach for developing customized and bioactive implants, scaffolds, and other regenerative medicine applications.

Indexed as

Biocompatible MaterialsCollagenPeptidesPolyestersPrinting, Three-DimensionalHumansMaterials TestingTensile StrengthTissue EngineeringTissue ScaffoldsX-Ray DiffractionBiocompatible MaterialsCollagenPeptidespolycaprolactonePolyesters3D printingBioactive materialsCollagen peptidesFilament fabricationPolycaprolactoneTissue engineering

Identifiers

PMID41444724
PMCPMC12738878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.